After Pfizer’s (NYSE:) decision to terminate the global collaboration and license agreement with Sangamo, the latter’s shares have dropped by approximately 27%.
The agreement’s termination is scheduled for April 21, 2025, prompting Sangamo to explore alternative options and potential partners for its program.
Pfizer’s choice to end the partnership is mainly related to its decision not to proceed with the Biologics License Application and Marketing Authorization Application submissions for giroctocogene fitelparvovec. Additionally, Pfizer has no intentions to pursue the commercialization of this specific biologic.
This article was created with the assistance of AI and reviewed by an editor. Refer to our T&C for more details.